Anavex Life Sciences Stock (NASDAQ:AVXL)
Previous Close
$9.02
52W Range
$3.25 - $10.45
50D Avg
$6.40
200D Avg
$5.30
Market Cap
$772.49M
Avg Vol (3M)
$997.14K
Beta
0.60
Div Yield
-
AVXL Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AVXL Performance
Peer Comparison
Ticker | Company |
---|---|
TGTX | TG Therapeutics, Inc. |
BTAI | BioXcel Therapeutics, Inc. |
IOVA | Iovance Biotherapeutics, Inc. |
EXEL | Exelixis, Inc. |
RNAZ | TransCode Therapeutics, Inc. |
VKTX | Viking Therapeutics, Inc. |
AXSM | Axsome Therapeutics, Inc. |
BIVI | BioVie Inc. |
KOD | Kodiak Sciences Inc. |
EYEN | Eyenovia, Inc. |
SAVA | Cassava Sciences, Inc. |
CGTX | Cognition Therapeutics, Inc. |
NVAX | Novavax, Inc. |
ANVS | Annovis Bio, Inc. |
INMB | INmune Bio, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |